

NIH funding opportunities

9 September 2024 (#26)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[Remember to “Flatten” PDF Files Before Submitting to NIH! A New Resource Explains How](#) NIH requires submission of PDF attachments as part of both the application process and post award activities in the eRA Commons. Flattening files keeps them from being inadvertently edited, reduces the file size, and helps ensure that what you submit is what agency staff members see.

[NOT-OD-24-169](#) Updating the Definition of Sexual and Gender Minority Populations in NIH-Supported Research. This notice announces a revision to the definition of sexual and gender minority (SGM) populations for NIH-supported research. This change in definition is intended to enhance inclusivity and does not exclude any person or population included under previous definitions of SGM populations for NIH. This notice is immediately effective upon.

[NOT-OD-24-163](#) NIH’s Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by **May 25, 2025 for **Applications** and **Research Performance Progress Reports (RPPRs)**.** The Common Forms represent a collaborative effort between federal research agencies to ensure standard disclosure requirements. In accordance with NIH’s Peer Review Regulations at [42 Code of Federal Regulations Part 52h](#), NIH currently plans to continue collecting three required agency specific data elements (i.e., Personal Statement, Contributions to Science, and Honors) to assess qualifications. **These data elements will be collected separately from the Common Forms on a new NIH Biographical Sketch Supplement.**

Biographical Sketch

- NIH will no longer accept the NIH Biographical Sketch format page.
- NIH will require the use of the Common Form for Biographical Sketch.
- NIH will require the use of a new NIH Biographical Sketch Supplement to collect the “Personal Statement,” “Contributions to Science,” and “Honors” statements.
- All Biosketches must be prepared on <https://www.ncbi.nlm.nih.gov/sciencv/>

Current and Pending (Other) Support

- NIH will no longer accept the NIH Other Support format page.
- NIH will require the use of the Common Form for Current and Pending (Other) Support.

Failure to use the required forms or format pages may cause NIH to withdraw your application from consideration. [NOT-OD-24-086](#) **New NIH "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2025.** All active [Parent](#) and IC-issued NOFOs with due dates on or after January 25, 2025, will be reissued or updated to add FORMS-I application packages.

Parent Announcements

[NOT-OD-24-099](#) **Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Funding Opportunity (NOFO)

[RFA-AI-24-071](#) **Promoting Innovative Research in *Treponema pallidum* Pathogenesis (R21 Clinical Trial Not Allowed).**

The purpose of this NOFO is to support basic and exploratory research projects to advance our understanding of *Treponema pallidum* bacterial pathogenesis.

Date: November 04, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of intent due 30 days prior to the application due date.

Budget: NIAID intends to commit \$2 Million in FY 2025 to fund 4–6 awards. Application budgets are not expected to exceed \$275,000 in direct costs for the two-year project period and should reflect the actual needs of the proposed project. No more than \$200,000 should be requested in any single year.

[RFA-AI-24-057](#) **Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed).** This purpose of this NOFO is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies.

Date: December 04, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of intent due 30 days prior to the application due date.

Budget: NIAID intends to commit \$1.2 M in FY 2025 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

[RFA-AI-24-064](#) **Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed).** This purpose of this NOFO is to support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies.

Date: December 04, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of intent due 30 days prior to the application due date.

Budget: NIAID intends to commit \$0.8 M in FY 2025 to fund 2-3 awards. Application budgets for NIH R21 grants are: \$275,000 in direct costs over a two-year project period, with a maximum of \$200,000 in direct costs in any given year. The scope of the proposed project should determine the project period. The maximum project period is two years.

[PAR-24-277](#) **Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed).** This NOFO encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes

of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Date: October 05, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

[PAR-24-291 Basic Research in Cancer Health Disparities \(R21 Clinical Trial Not Allowed\)](#). This NOFO encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the NOFO will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.

Date: October 16, 2024. All applications are due by 5:00 PM local time of applicant organization.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

[RFA-AG-25-031 Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries \(LMICs\) for Aging and Alzheimer's Disease \(AD\) and AD-Related Dementias \(ADRD\) Research \(R03 Clinical Trial Not Allowed\)](#). This NOFO invites R03 applications from institutions in low- and middle-income countries (LMICs), as defined by the [World Bank](#), to support junior faculty investigators involved in aging and Alzheimer's Disease (AD) and AD-related dementias (ADRD) from these institutions. The goals of this NOFO are the following:

1. To support the aging and/or AD/ADRD research conducted by junior faculty investigators from institutions in LMICs; and
2. To support the career development of junior faculty investigators from institutions in LMICs as future leaders in aging and AD/ ADRD.

In support of the program's goals, this NOFO invites applications that will yield pilot data, resources, and experience for subsequent aging and AD/ADRD research projects. In addition, candidates are encouraged to seek out a supportive research environment that will achieve the goal of **fostering the career development** of junior investigators.

Date: November 07, 2024; February 14, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIA intends to commit a total of \$1.08M in FY 2025 and FY 2026 to fund 6 awards for AD/ADRD and 4 awards for aging research. Application budgets are limited to \$100,000 in direct cost per year. The project period is limited to 2 years.

[RFA-AG-25-032 Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries \(U01 Clinical Trial Not Allowed\)](#). This NOFO aims to promote collaborative research programs by inviting applications to support innovative and sustainable Alzheimer's disease (AD) and AD-related dementias (ADRD) (including frontotemporal dementia (FTD), Lewy body dementia (LBD), vascular cognitive impairment/dementia (VCID), and mixed etiology dementias (MEDs)) neuroscience research for experienced investigators in low- and middle-income countries (LMICs). These collaborative research programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience capacity and research, ultimately leading to prevention and mitigation strategies for AD/ADRD in LMICs. This NOFO supports applications submitted from LMIC institutions as defined by the [World Bank](#). LMIC scientists are expected to collaborate with scientists from the United States.

Date: November 07, 2024; February 14, 2025. All applications are due by 5:00 PM local time of applicant organization.

Budget: NIA intends to commit \$2.16M in FY 2025 and FY 2026 to fund 5 awards. Application budgets are limited to \$400,000 in direct cost per year. The project period is limited to 5 years.

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add “*Interest in NIH opportunity*” in the subject line.

Add the *notice number with hyperlink* in the text of the email.